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Objective: The aims of this study were to assess the useful-
ness of functional magnetic stimulation in controlling neuro-
genic bowel dysfunction in spinal cord injured patients with 
supraconal and conal/caudal lesions, and to investigate the 
efficacy of this regimen with a 3-month follow-up.
Design: A longitudinal, prospective before-after trial.
Subjects: A total of 22 patients with chronic spinal cord in-
jured and intractable neurogenic bowel dysfunction. They 
were divided into group 1 (supraconal lesion) and group 2 
(conal/caudal lesion). 
Methods: The colonic transit time assessment and Knowles-
Eccersley-Scott Symptom Questionnaire were carried out for 
each patient before they received a 3-week functional magnetic 
stimulation protocol and on the day following the treatment. 
Results and conclusion: Following functional magnetic 
stimulation, the mean colonic transit time for all patients de-
creased from 62.6 to 50.4 h (p < 0.001). The patients’ Know-
les-Eccersley-Scott Symptom scores decreased from 24.5 to 
19.2 points (p < 0.001). The colonic transit time decrement 
in both group 1 (p = 0.003) and group 2 (p = 0.043) showed 
significant differences, as did the Knowles-Eccersley-Scott 
Symptom score in both groups following stimulation and in 
the 3-month follow-up results (p < 0.01). The improvements 
in bowel function indicate that functional magnetic stimula-
tion, featuring broad-spectrum application, can be incorpo-
rated successfully into other therapies as an optimal adju-
vant treatment for neurogenic bowel dysfunction resulting 
from spinal cord injury.
Key words: constipation, functional magnetic stimulation, neuro-
genic bowel dysfunction, spinal cord injury.
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INTRODUCTION
Neurogenic bowel dysfunction (NBD) is recognized as a major 
physical difficulty, especially among patients with chronic 
spinal cord injury (SCI). NBD impairments include difficulty 
with evacuation, abdominal distension, faecal impaction and 
faecal incontinence. These symptoms are highly prevalent in 
patients with SCI, affecting 41–86% of patients (1, 2). Even 
when undergoing extensive medical treatment (1, 3–6), com-
bined with digital stimulation or manual evacuation, most 
patients with SCI still experience refractory constipation. 
As many as 41% of patients spend more than 1 h every day 
on bowel care and patients with SCI have rated this problem 
as a moderate to severe life-limiting disability (4, 5). These 
observations imply that the current medical methods available 
to reduce the functional impact of NBD on daily life have only 
a limited effect.
Recent advances in rehabilitation and surgical interventions 
have offered patients alternative bowel care programmes. 
Electrical stimulation to the sacral roots or sacral dermatomes 
has had some success in bowel elimination, but also has con-
siderable disadvantages (7–9). Implanting a neuroprosthesis 
requires surgery and has the risks of abolishing reflex erec-
tion and reflex ejaculation (after dorsal rhizotomy). In one 
study with a 12-month observation, 80% of patients who had 
undergone neuroprosthesis implantation were still relying on 
manual evacuation to remove remaining stool. Research on 
surface electrical stimulation of sacral dermatomes to facilitate 
the somatovisceral reflex has found that stimulation does not 
seem to result in actual bowel emptying, despite an increase 
in the number of colonic spike waves (10). 
Functional magnetic stimulation (FMS), on the other hand, 
is capable of directing stimulation of the spinal nerves and 
contraction of deep muscles to facilitate bowl elimination 
without surgical procedures or unnecessary tissue damage. 
This technique has been developed to aid expiratory functions, 
micturition and bowel elimination in a non-invasive manner 
(11–15). In one study that assessed the effect of FMS on 6 
patients with SCI, notable increases in rectal pressure and 
suppression of hyperactive rectal contractions were found to 
have taken place (16). In another study, 4 patients with SCI 
experienced improvement in their bowel routines after 3 weeks 
of FMS conditioning, with evidence of shortened colonic 
transit time (CTT) (17). However, it is still not known whether 
this repeated magnetic pulsation produces a cumulative effect 
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on the nervous system. More research needs to be carried out 
with larger numbers of patients with SCI with NBD to verify 
whether FMS produces consistent results. Given both the po-
tential of FMS for treating patients with SCI with NBD, and 
considering the ambivalence that still exists over how it affects 
the nervous system, the present study was firstly designed to 
recruit larger patient groups with a longer follow-up period.
SCI lesions are traditionally classified into supraconal or conal/ 
caudal lesions, according to pathophysiological and clinical 
implications (18–21, 22). Apart from evidence suggesting that 
FMS can induce physiological changes in supraconal SCI, it 
has not been established whether it influences conal/caudal le-
sions as well. Nevertheless, these patients manifest a different 
type of NBD, which has so far yielded very disappointing treat-
ment results, and is certainly worthy of further investigation.
We included both supraconal and conal/caudal patients with 
SCI in this study to test the effectiveness of FMS on each of 
these pathologies and to compare their responses to FMS 
treatment. We also included these patients in order to identify 
patient characteristics that predict a good response to treatment; 
and to assess the usefulness of this regimen in patients with 
SCI with a 3-month follow-up.
METHODS
Participants
Patients with traumatic SCI and intractable constipation were recruited 
prospectively to this study from the SCI centre of Taipei Veterans 
General Hospital between January 2005 and December 2006. Spinal 
cord or roots lesions had been confirmed in previous electrophysio­
logical studies and magnetic resonance imaging surveys; and most 
of the patients had already undergone surgical decompression and 
neural repair. We followed the modified Rome criteria for the defini-
tion of constipation: “2 or fewer bowel movements a week, the use 
of laxatives or enema more than once a week or digital evacuation 
of faeces on all occasions” (1). None of the patients was satisfied 
with their existing bowel routine. During this time, 43 patients with 
SCI for over 6 months and fully recovering from spinal shock were 
eligible for inclusion.
Full physical and history examinations, including motor function, 
sensory function, and spinal sacral reflex testing, were carried out 
to determine the neurological condition of our patients. We used the 
American Spinal Injury Association (ASIA) Impairment Scale to as-
sess the extent of each patient’s injury. 
Eighteen of the original 43 patients were eventually excluded from 
this study for the following reasons: patients with SCI with complete 
conal/caudal spinal cord lesions (n = 2), since in previous testing pa-
tients with this condition have not responded with rectal pressure or 
pressure change following magnetic stimulation (17). The patients who 
were characterized by severe faecal incontinence will be investigated in 
further studies. Patients with diseases or conditions that are capable of 
complicating neurogenic bowel problems, such as Parkinson’s disease 
(n = 2), stroke sufferers (n = 3), traumatic brain injury (n = 1) or patients 
with a history of peripheral neuropathy such as diabetics or metabolic 
neuropathy patients (n = 3), were excluded from the study. Also, in 
the exclusion criteria were patients with cardiac pacemakers or other 
metallic devices (n = 2) that risk being damaged or displaced; as well 
as patients with a history of uncontrolled high blood pressure (n = 5) 
or major abdominal surgery, which may cause adverse side-effects 
during treatment. (Fig. 1)
The impairment of colonic function was found to be associated with 
several neurological characteristics. These characteristics include pa-
tients’ neurological levels (3), the patterns of their SCI and their degree 
of mobility (23). Patients with a higher neurological SCI level, who 
suffer from complete lesions and are non-ambulatory, tend to be more 
dependent on assistance with bowel hygiene (23). Using these tenden-
cies as a guide, we divided our patients into the following groups: (i) 
group 1: patients with supraconal lesions; and group 2: patients with 
incomplete conal/caudal lesions; (ii) group A: patients with complete 
spinal cord lesions; and group NA: patients with incomplete spinal 
cord lesions; (iii) group S: patients who were capable of standing; 
and group NS: patients who were incapable of standing. Grouping 
patients according to these characteristics was a key step in isolating 
the factors that enable patients with SCI to respond to FMS, both in 
this and possible future studies.
All of the group 2 subjects had preserved anal superficial sensation 
and spinal sacral reflexes (bulbocavernosus reflexes), which ensured 
nerve continuity in the circumstance of receiving magnetic stimula-
tion. Group A corresponded with grade “A” in the ASIA impairment 
scale (patients with complete spinal cord lesions), and group NA 
corresponded with groups “B”, “C”, or “D” in the ASIA Impairment 
Scale (incomplete lesions). The group S patients were ambulatory or 
could stand with pelvic belt support for more than 1 h per day, and 
the group NS patients were bedridden or wheelchair bound. This 
study adhered to the Occupational Health and Safety Administration 
regulations, and was approved by the local institutional review board. 
Informed consent was obtained from all patients.
Stimulation protocol
A Medtronic MagPro R30 Magnetic Stimulator (Medtronic A/S, Skov-
lunde, Denmark) was used for this conditioning protocol. This stimula-
tor can generate a maximal field strength of 2.2 tesla at the centre of the 
coil. This protocol was developed as part of a pioneering experiment 
by Lin et al. (17) after the most effective parameter setting with respect 
to the rise in rectal pressure was determined. We adopted the protocol 
Fig. 1. Consort flow­chart diagram outlining the progress of participants. 
Patients who completed the evaluations were included in the statistical 
analyses. Those who continued the follow-up evaluations were included 
in the analyses for long-term effect. SCI: spinal cord injury; AD: 
autonomic dysreflexia; Medications* = anticholinergic agents, tricyclic 
antidepressants, anti-hyperlipidaemia agents, and compounds containing 
codeine, calcium and caffeine.
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for this study, and followed its general principles for administrating 
our own research. During hospitalization, each patient underwent a 
3-week stimulation period, consisting of 20-min stimulation sessions 
twice a day. Each session contained 10 min of thoracic nerve stimula-
tion with the centre of the coil placed at the T9 spinal process, and 
another 10 min of lumbosacral nerve stimulation with the coil at the 
L3 spinal process. The patients underwent stimulation from a sitting 
position. The stimulation intensities were set at 50% on the first day, 
60% on the second day, and then stabilized at 70% for the remaining 
days. The stimulation frequency, burst length, and interburst intervals 
were fixed at 20 Hz, 2 sec, and 28 sec, respectively. 
Evaluation methods
We adopted a simplified version of the CTT assessment protocol 
(24) for this study because it involves less radiation exposure. CTT 
utilizes 3 distinct marker types (Sitzmark radiopaque capsule (Konsyl 
Pharmaceuticals, Inc. Easton, USA)) that the patient ingests 1 by 1 
on 3 consecutive days, followed by a single abdominal radiograph to 
visually record the numbers of each kind of marker. We carried out the 
CTT assessment for each patient before they received FMS treatment 
and on the day following the treatment. During CTT testing, all of 
the patients followed a normal hospital diet, but each had to suspend 
laxative medication, enema usage or digital manoeuvring for 3 days 
to avoid any disturbance of colonic motility. CTT was calculated by 
applying the following equation:
CTT = N1 + N2 + N3
where “N1” means the total number of the first type of marker present 
in a given film, N2 = number of the second type of marker present, and 
N3 =number of the third type of marker present. Localization of markers 
on abdominal films relied on the identification of bony landmarks and 
gaseous outlines as described by Arhan and colleagues (25). Retention 
of all 72 markers on day 4 following treatment yielded an estimated 
transit of 72 h, a value of the upper limit by this method.
The Knowles-Eccersley-Scott Symptom (KESS) questionnaire was 
performed before the FMS intervention, and on the day finishing the 
protocol. Between 2 weeks and 3 months after the intervention, it 
was also followed up by telephone at 2-week intervals. Table I lists 
the details of the questionnaire. Items include the frequency of bowel 
movement using existing therapy, difficulty of evacuation, laxative use, 
and time taken in the lavatory for bowel evacuation attempts. Since 
the duration of constipation in our before-and-after trial remained 
consistent, our version of the KESS questionnaire omitted the original 
question about the duration of constipation (26).
Data analysis
The values obtained on the CTT test and from the KESS for all the 
patients were compared from baseline to post-FMS with the Wilcoxon 
signed-rank test. Meanwhile, the non-parametric Mann-Whitney U 
test was used for inter-group comparisons (group 1 vs 2, group A vs 
NA, and group S vs NS). To account for the repeated measurements’ 
dependency, we used the generalized estimating equations (GEE) 
method (27) to examine the improvements in the series of KESS scores 
in comparison with the baseline values, representing the patients’ 
clinical progression during 3 months of follow-up. Statistical tests 
were declared statistically significant if p < 0.05.
RESULTS
Patient demographics
Twenty-two patients met the aforementioned inclusion criteria. 
Their relevant characteristics, including neurological levels 
and bowel management methods, are listed in Table II. There 
were 19 men and 3 women, age range 22–65 years, with a 
mean age of 46.7 years. The mean duration of the injury was 
38.6 months. Among these patients, 15 had supraconal lesions, 
Table I. Distribution (%) among the Knowles-Eccersley-Scott Symptom 
(KESS) questionnaire items at baseline and post- functional magnetic 
stimulation (FMS) intervention for 22 patients with spinal cord injury
Symptoms Scale
Base-
line
Post-
FMS p
Laxative use
None
Occasionally or short duration usage
Regular or long duration usage
Long duration, ineffective
1
2
3
4
27
23
50
0
55
13
32
0
0.023*
Frequency of bowel movement (using 
current therapy)
1–2 times per 1–2 days
2 or less times per week
Less than once per week
Less than once per 2 weeks
1
2
3
4
86
14
0
0
86
14
0
0
1.00
Unsuccessful evacuation 
Never/rarely
Occasionally
Usually
Always (manual evacuation)
1
2
3
4
9
27
23
41
27
36
14
23
0.016*
Feeling of incomplete evacuation
Never
Rarely
Occasionally
Usually
Always
1
2
3
4
5
14
14
18
23
32
32
18
18
14
18
0.017*
Abdominal pain 
Never
Rarely
Occasionally
Usually
Always
1
2
3
4
5
68
5
18
4.5
4.5
68
14
14
0
4
0.25
Bloating
Never
Perceived by patient only
Visible to others
Severe, causing nausea
Severe, with vomiting
1
2
3
4
5
41
32
18
9
0
50
41
4.5
4.5
0
0.12
Enema/digitations
None
Occasional enema/suppository usage
Regular enema/suppositories usage
Occasional manual evacuation 
Manual evacuation always
1
2
3
4
5
0
18
27
50
5
0
32
23
45
0
0.08
Time taken (minutes at each evacuation 
/evacuation attempt)
< 5 
5–10 
10–30 
 > 30 
1
2
3
4
0
18
59
23
9
59
27
5
< 0.001*
Difficult evacuation causing painful effort
Never
Rarely
Occasionally
Usually
Always
1
2
3
4
5
14
0
9
27
50
45
5
9
23
18
0.001*
Stool consistency
Soft/ loose/ normal
Occasionally hard
Always hard
Always hard, usually pellet-like
1
2
3
4
59
23
14
4
86
14
0
0
0.02*
*Wilcoxon signed­rank test showed significant differences at p < 0.05.  
Reproduced with permission from Springer Verlag (26). 
Rarely = < 25%; occasionally = 25–50%; usually = > 50% of the time.
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and constituted group 1; the remaining 7 had incomplete conal/
caudal lesions and comprised group 2. The patient numbers of 
groups A, NA, S, and NS were 6, 16, 14 and 8, respectively. 
Colonic transit time
The individual and mean CTT are shown in Tables II and 
III, respectively. Seven cases manifested marked prolonged 
CTT of over 72 h, an upper-limit value according to the CTT 
method. For ethical reasons, we processed the CTT data with 
this value without prolonging the observation period, since all 
our patients were prohibited from using laxatives and enemas 
during the CTT testing. The mean colonic transit time for all 
patients decreased from the baseline value of 62.6 h to 50.4 h 
after FMS stimulation, with a p-value of < 0.001. Significant 
improvements were also found in CTT for group 1 (p = 0.003), 
group 2 (p = 0.043) and the other groups (Table III). There was 
no baseline difference for the inter-group comparisons. The 
inter-group comparisons of CTT differences, including groups 
1 and 2 (p = 0.49), groups A and NA (p = 0.48), and groups S 
and NS (p = 0.26), did not achieve statistical significance.
Knowles-Eccersley-Scott Symptom questionnaire
Table I describes the details of our patients’ pre- and post-
FMS bowel functions. Among them, the scores for frequency 
of laxative use, unsuccessful evacuation attempts, feeling of 
incomplete defecation, difficulty with evacuation, and time 
taken showed significant decreases (p < 0.02). 
The total score of the questionnaire for all patients showed a 
significant decrease when compared with baseline data (24.5 to 
19.2, p < 0.001). In group 1, the mean score on baseline evalua-
Table II. Clinical characteristics of 22 patients with spinal cord injury (SCI) 
Patient
Neurological 
level ASIA class Age, years
Months post-
injury Bowel care Standing
Colonic transit 
time, h Score
Group 1
1 C4 A 30 54 Lax + Ene No 71 29
2 C6 D 53 144 Ene Yes 69 30
3 C6 A 22 47 Lax + Ene No 71 32
4 C5 C 26 15 Lax + Ene Yes 72 25
5 C7 B 62 18 Lax + Ene No 53 16
6 T6 A 36 22 Lax + Ene Yes 36 28
7 C4 C 52 13 Ene No 55 22
8 C3 B 34 21 Lax + Ene No 72 26
9 C5 A 56 18 Lax + Ene No 72 19
10 T6 A 27 36 Lax + Ene Yes 72 22
11 T3 B 35 9 Lax Yes 72 24
12 C4 A 55 35 Lax No 24
13 C8 B 25 7 Lax + Ene No 58 20
14 C4 D 42 31 Ene Yes 72 32
15 T6 C 42 24 Ene Yes 25
Group 2
1 L2 D 76 74 Dig yes 36 21
2 T12 C 46 120 Lax + Dig yes 40 25
3 T12 C 76 18 Lax + Dig yes 67 29
4 L4 C 79 120 Ene yes 26
5 T11 B 62 7 Lax + Ene yes 25
6 L3 B 24 7 Dig yes 72 17
7 T12 B 65 9 Lax yes 67 23
C: cervical level; T: thoracic level; L: lumbar level; ASIA: American Spinal Injury Association classification; Lax: laxatives; Ene: enema; Dig: 
digital evacuation.
Table III. Data summary of the colonic transit time (hours) and score of Knowles-Eccersley-Scott Symptom (KESS) questionnaire at baseline and 
after functional magnetic stimulation (FMS) conditioning
Colon transit time, mean (SD) Total questionnaire score, mean (SD)
Baseline Post-FMS p Baseline Post-FMS p
Group 1 65.0, 11.2 53.6, 16.5 0.003 24.9, 4.7 19.1, 4.7 0.001
Group 2 56.4, 17.0 42.0, 16.1 0.043 23.7, 3.9 19.4, 4.5 0.026
Group A 65.9, 13.3 54.6, 16.0 0.04 24.2, 5.1 19.0, 5.7 0.017
Group NA 60.5, 13.3 47.7, 17.5 0.002 24.7, 4.1 19.4, 4.0 0.001
Group S 61.4, 15.6 51.7, 18.0 0.017 25.1, 3.9 20.0, 4.0 0.007
Group NS 64.6, 8.8 48.3, 15.6 0.007 23.5, 5.3 17.9, 5.4 0.003
All subjects 62.6, 13.1 50.4, 16.7 < 0.001 24.5, 4.4 19.2, 4.6 < 0.001
SD: standard deviation; Group 1: patients with supraconal lesions; Group 2: patients with incomplete conal/caudal lesions; Group A: patients 
with complete spinal cord lesions; Group NA: patients with incomplete spinal cord lesions; Group S: patients who were capable of standing; 
Group NS: patients who were incapable of standing.
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tion was 24.9, then decreased to 19.1 after FMS stimulation 
(p = 0. 001). In group 2, the mean baseline score was 23.7, and 
improved to 19.4 after intervention (p < 0.05). Table III lists 
the results for the other groups. There was no baseline differ-
ence for the inter-group comparisons. In an analysis of groups 
1 and 2 (p = 0.43), groups A and NA (p = 0.61), and groups S 
and NS (p = 0.61), the magnitude of change in the scores did 
not reach statistical significance.
Therapeutic effect follow-up
The results of the questionnaires carried out 12 weeks fol-
lowing intervention are illustrated in Table IV. Among the 
22 participants, 9 persons (7 from group 1, 2 from group 2) 
completed the full 12 weeks of telephone evaluations. We 
excluded the other 13 patients from this part of the experiment 
because they took additional medication such as anticholinergic 
agents, tricyclic antidepressants, anti-hyperlipidaemia agents, 
or compounds containing codeine, calcium, and caffeine, which 
can interfere with colonic motility.
Using the GEE method, we found significant improvement 
in scores from the second to the eighth evaluation, lasting for 
the whole 12-week observation with the p-value varying from 
< 0.001 to 0.007. Compared with the baseline score, the great-
est improvement of 8.1 points occurred just after FMS admin-
istration. The effect was maintained overall, with a slight drop 
(3.4 to 5.6 points difference) over the follow-up period.
DISCUSSION
This study demonstrated the efficacy of FMS in controlling 
NBD in patients with SCI with both supraconal and incomplete 
conal/caudal lesions. The effect of FMS was not influenced by 
variables such as lesion completeness and degree of mobility. 
The present study is the first to date that has shown that FMS 
produces a consistent and broad effect on patients with varying 
manifestations of SCI with NBD. 
Although the storage and propulsion of stool acts mainly 
through the intrinsic nervous system in an enteric reflex man-
ner, the loss of autonomic spinal reflexes does indeed disturb 
colorectal motility and coordinated external sphincter relaxa-
tion during defecation (27). A supraconal lesion manifests a 
spastic hyperactive colon, combined with a tight dyssynergic 
pelvic floor. In contrast, a conal/caudal lesion manifests a 
flaccid hypoactive rectum and a suppressed rectoanal inhibi-
tory reflex (3, 19). A supraconal lesion results in generalized 
prolonged colonic transit throughout the colon, whereas conal/
caudal injuries result in prolonged rectosigmoid transit and 
severely compromised emptying at defecation (19, 20). The 
present study particularly addresses the usefulness of FMS in 
cases of both supraconal and conal/caudal SCI, for generating 
significant improvement on severe constipation, as documented 
in improved CTT and KESS questionnaire score.
The exact mechanisms through which FMS ameliorates NBD 
in patients with SCI remain inconclusive. There are several 
reasonable speculations as to the possible pathways. Firstly, 
the process of neuromodulation may be generated at the injured 
spinal level and pass through the descending serotonergic 
sprouting to the caudal segments, following the process of 
spinal plasticity (28, 29). The poly synaptic sacral reflex can be 
reorganized through repetitive FMS, with the result of reducing 
sacral reflex latency (13). The second possible mechanism is 
through enteric and pre-vertebral ganglia, releasing appropriate 
neurotransmitters in sequence. The direct modulation of the 
myenteric plexus, ganglia and interneuron connections may 
facilitate colon motility not only in supraconal patients with 
SCI, but also patients with partial and complete conal/caudal 
lesions. The third possible mechanism is through abdominal 
muscle contraction. When the magnetic coil is placed at T9, 
the spinal nerves between T6 and T12, with the correspond-
ing innervated abdominal muscles, may all be activated, re-
sulting in massive abdominal contraction. The massage-like 
exercise may thus trigger enteric nervous system activity via 
pressure-sensitive nerves, make further transmissions to the 
central nervous system through the autonomic ganglia (27), 
and release excitatory neurotransmitters at the enteric neu-
rons (30). Abdominal massage, adjuvant to traditional bowel 
programmes for patients with SCI, has already been proven 
to facilitate total CTT (31). 
Among the items of the KESS questionnaire, patient satis-
faction was greatest in “time taken for each evacuation” and 
“difficult evacuation” (p < 0.01). These variables were found to 
be closely related to the disordered defecation in constipation 
(25). Based on these findings, FMS can improve constipation 
complicated by the issue of difficulty with evacuation. If, as 
we speculated, FMS prompts the polysynaptic sacral reflex and 
consequently shortens the time of response to enemas or digi-
tations, the lessening of difficulty with evacuation among our 
patients might be explained by the activation of this mechanism 
by FMS. From this viewpoint, complete evacuation seems to 
be achievable with our protocol and results in less effort, more 
successful evacuation attempts (p = 0.01), and less feeling of 
incomplete evacuation (p = 0.016).
The other anticipated finding in this study was the decrease in 
laxative use (p = 0.02), which was found to be closely related to 
the improvement in CTT (25). The therapeutic benefit of FMS 
Table IV. Points and differences of follow-up questionnaires compared with baseline data in 9 patients
Baseline Post FMS 2nd week 4th week 6th week 8th week 10th week 12th week
Mean (SD) 23.8 (4.2) 15.7 (3.5) 18.1 (4.8) 20 (4.8) 19.9 (5.6) 19.6 (4.6) 20.3 (5.4) 20 (4.4)
Difference 8.1 5.7 3.8 3.9 4.2 3.4 3.8
p-valuea < 0.001 < 0.001 0.001 0.004 < 0.001 0.007 < 0.001
ap-values obtained from generalized estimating equations (GEE) method.
FMS: functional magnetic stimulation; SD: standard deviation.. 
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was not reflected in the domains of bowel frequency and enema 
use, because in situations of such serious constipation, as with 
the patients in this study, enema or digitation still needs to be 
performed every day or every other day, as part of the general 
discipline of rehabilitation programmes. 
Abdominal pain and bloating were often experienced by 
patients with SCI, even those with complete lesions. It has 
been hypothesized that this sensation, arising from the rectum, 
is able to bypass the injured spinal cord and ascend through 
sympathetic afferents and the cervical or thoracic intergan-
glionic fibres to the supraspinal connection. The properties of 
such pain have been suggested to be part of the central pain 
of the injury or to be associated with psychological distress 
or somatic pain syndrome (32). The other possibility is that 
abdominal pain or bloating occurs as a result of the discomplete 
lesion, in which a clinically complete SCI is accompanied by 
neurophysiological evidence of a residual neural connection to 
the brain (33). Given that such sophisticated generators lead to 
these syndromes, it is not surprising that the scores of these 2 
items did not show significant change after our intervention.
We divided all patients into groups of complete and in-
complete injuries according to the ASIA Impairment Scale, 
and assumed that a complete lesion is less receptive than 
an incomplete lesion to modulation by FMS. However, our 
investigation disproved this hypothesis. Our data with the 
CTT and questionnaire score indicated that a complete lesion 
had no more preferential effect than an incomplete lesion on 
an SCI patient’s ability to respond to FMS. The same pattern 
was found between the standing and non-standing groups. The 
standing (S) group comprised either grade C to D tetraplegics 
or grade A to D paraplegics (Table II), and represented stronger 
abdominal and back control for maintaining upright posi-
tion, in contrast with those in the incapable-of-standing (NS) 
group, who were bedridden or wheelchair-bound. The group 
S patients were supposed to have enough gravity stimulation 
for defecation, and therefore have a better a prognosis for FMS 
treatment. But the result obtained in this study contradicted 
this assumption. The characteristic of standing ability did not 
improve the efficacy of FMS. Our findings emphasized that 
the effect of neuromodulation for successful bowel functioning 
takes place through the enteric nervous system and autonomic 
pathways or through spinal reorganization, rather than being 
influenced by the above hypothesized factors.
This study has several limitations. Firstly, we did not design a 
randomized, double-blind controlled model. On the other hand, 
the intractable constipation of most of the chronic patients with 
SCI was refractory to various medical treatments they had already 
tried during a considerable time-span. The severity of their NBD 
had reached a stable condition, which would not simply improve 
with time. Therefore, in our opinion, the before-after nature of 
this trial was valid, and its results were reliable. The fact that 13 
patients had to be excluded from the 12-week follow-up period 
had consequences for the reliability of the long-term results. To 
better confirm the reliability the results achieved in this study, 
more research needs to be carried out with larger numbers of 
follow-up patients. Overall, this was a preliminary study that 
followed the guidelines of the pioneering research on FMS in 
patients with SCI by Lin et al. (17), and continued to explore the 
usefulness of FMS in varied patient populations.
Secondly, the KESS questionnaire was designed to assess 
and diagnose functional constipation, and was not validated 
for doing the same for NBD. By the initiation of our study in 
January 2005, no known validated scoring system existed for 
NBD. The “Neurogenic bowel dysfunction score” (34), pub-
lished in 2006, comprised questions for both the constipation 
and incontinence symptoms that were often experienced in 
NBD patients. However, the KESS score comprised various 
questions that distinguishing the subgroups of constipation, 
and was therefore also feasible for monitoring the efficacy of 
treatment for constipation. It was the most appropriate scoring 
system to use when we initiated the study, and, taking these 
factors into account, it has proved a reliable scoring system 
to use.
Despite all the patients stopped laxatives 2 days before the 
CTT examination, we found that 6 out of the 22 patients had 
relatively shorter baseline CTT (< 60 h) in comparison with 
previous research (17, 20). The differences in CTT may be due 
to variations in diet between Taiwan and western countries. 
Possible explanations will be investigated in a future study.
In conclusion, this is the first study to date which has dem-
onstrated the wide-spectrum effect of FMS in patients with 
SCI with NBD characterized by severe constipation. The 
outcomes of our study have demonstrated that further inves-
tigation should take place on the optimal parameters setting 
of magnetic stimulation for other bowel problems, such as 
neuropathic pain syndrome or faecal incontinence in complete 
conal/caudal SCI. We have successfully demonstrated the con-
sistent and broad effects of FMS on a general SCI population. 
At the same time, strategies for establishing more practical 
and appropriate research settings for investigating FMS use 
with SCI NBD patients are in continual development. FMS 
should be available as a proper alternative as a fundamental 
treatment in intractable NBD, and a complementary strategy 
to traditional therapies.
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